Christensenella Minuta Buy !!TOP!!
A novel, strictly anaerobic, non-motile, non-spore-forming, Gram-negative, short, straight rod with tapered ends, designated YIT 12065(T), was isolated from human faeces. Strain YIT 12065(T) was saccharolytic and negative for catalase, oxidase and urease, hydrolysis of aesculin and gelatin, nitrate reduction and indole production. The end products of glucose fermentation were acetic acid and a small amount of butyric acid. The DNA G+C content was 51.3 mol%. The predominant fatty acids were iso-C(15:0), C(16:0) and C(14:0). Respiratory quinones were not detected. The cell wall contained glutamic acid, serine, alanine and ll-diaminopimelic acid. The whole-cell sugars were ribose, rhamnose, galactose and glucose. Phylogenetic analyses based on 16S rRNA gene sequences using three treeing algorithms revealed that the strain formed a novel family-level lineage within the phylum Firmicutes, class Clostridia, order Clostridiales. Caldicoprobacter oshimai JW/HY-331(T) was shown to be the closest named relative on the basis of 16S rRNA gene sequence similarity (86.9%), followed by Tindallia californiensis DSM 14871(T) (86.3%) and Clostridium ganghwense JCM 13193(T) (86.1%). Similar 16S rRNA gene sequences (98.6-96.7%) were found amongst faecal uncultured clones of human and dugong (Dugong dugon). They clustered with strain YIT 12065(T) in a distinct and deep evolutionary lineage of descent in the order Clostridiales. The distinct phylogenetic position supports the proposal of Christensenella gen. nov., with the type species Christensenella minuta sp. nov. (type strain YIT 12065(T) =DSM 22607(T) =JCM 16072(T)). A new family Christensenellaceae fam. nov. is also proposed.
christensenella minuta buy
Christensenellaceae is a family of subdominant commensal bacteria found in humans. It is thought to play an important role in gut health by maintaining microbial symbiosis. Indeed, these bacteria occur at significantly lower levels or are absent in individuals suffering from inflammatory bowel diseases (IBDs). Here, we explored if type species Christensenella minuta (strain: DSM 22607) could have the potential to help treat IBDs. We assessed key properties displayed by the bacterium using a combination of in vitro and in vivo assays. We found that while C. minuta is a strict anaerobe, it is also oxygen tolerant. Additionally, we observed that the species produces high levels of acetate and moderate levels of butyrate. We performed deep phenotyping using Biolog microarrays. Using human intestinal cell lines, we discovered that C. minuta demonstrated strong anti-inflammatory activity, resulting in reduced levels of proinflammatory IL-8 cytokines via the inhibition of the NF-κB signaling pathway. Furthermore, C. minuta protected intestinal epithelial integrity in vitro. Finally, in two distinct animal models of acute colitis, C. minuta prevented intestinal damage, reduced colonic inflammation, and promoted mucosal healing. Together, these results indicate that C. minuta has potent immunomodulatory properties, underscoring its potential use in innovative microbiome-based IBD biotherapies.
Two gut bacteria are associated with lean body weight. Akkermansia muciniphila and Christensenella minuta. They are good gut bacteria for weight loss because they are linked with preventing weight gain and are often found in slim individuals.
Arm Intervention/treatment Experimental: normal weight healthy adult volunteers receiving Xla1one capsule Xla1 given once daily Drug: Xla1Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta) Experimental: overweight and class 1 obese adult patients receiving Xla1one capsule Xla1 given once daily Drug: Xla1Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta) Placebo Comparator: overweight and class 1 obese adult patients receiving placeboone capsule placebo given once daily Drug: PlaceboMatching placeboOther Name: Matching placebo Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : number of patients experiencing adverse events [ Time Frame: 12 weeks ]To assess the safety and tolerability of Xla1 in Healthy adult Volunteers (HV) [part 1], and, subsequently, in overweight and class I obese adults [part 2]. Secondary Outcome Measures : Modulation of the gut microbiota composition [ Time Frame: 12 weeks ]To evaluate the effects of Xla1 on subject's intestinal microbiome ecology Quantification of Xla1 presence in stools during the study [ Time Frame: 12 weeks ]To evaluate the engraftment of Xla1 in the gastrointestinal tract (GIT) Eligibility CriteriaGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Layout table for eligibility information Ages Eligible for Study: 19 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria For Healthy Volunteers (Part 1)
Christensenella minuta is a recently described gastrointestinal bacterium that plays a significant role in the prevention of obesity. Here, Creative Biolabs provides a comprehensive range of high-quality services and support for the development of probiotics based on Christensenella minuta.
Christensenella minuta (C. minuta) is a recently identified as a gram-negative bacterium belonging to the genus of Christensenella and the family of Christensenellaceae. C. minuta was first discovered in 2012 from the feces of a healthy donor. As a Gram-negative bacterium, C. minuta mainly distributes in the human gastrointestinal tract, which is a strictly anaerobic environment.
As a critical microbiome in the human gut, C. minuta has been indicated to be closely associated with human health improvement in an unknown biological mechanism. Numerous fecal samples research demonstrated that the presence or absence and amount of C. minuta could affect the obesity and related metabolic disorders risk of an individual. C. minuta tended to be more abundant in individuals with low body mass index (BMI) or lean body. Also, it has been found that C. minuta was highly heritable, and had an impact on obesity-associated microbiomes and other heritable probiotic bacteria in human and mice gut.
All this evidence suggests the great potential and possible therapeutic uses of C. minuta as probiotics in terms of obesity and related gastrointestinal disorders. A full understanding of C. minuta genome and its possible biological mechanisms will help us better understand not only the relationship between C. minuta and obesity and gastrointestinal diseases but also the relationship between host genetics and intestinal microbiome, meanwhile, it may also open the door to the development of probiotics therapies and live biotherapeutics.
Christensenella is a genus of non-spore-forming, anaerobic, and nonmotile bacteria from the family Christensenellaceae. The species C. minuta has been published and validated, and C. timonensis and C. massiliensis have been proposed as novel species of the genus Christensenella, all isolated from human feces. C. minuta in the gut has been associated with reduction in body weight and adiposity of mice. In a test on 977 volunteers, humans with higher levels of Christensenella in their guts were found to be more likely to have a lower body mass index than those with low levels. Christensenella are better represented in persons who are metabolically healthy. However, there is a link to possible pathogenic qualities of C. minuta in humans. An 18-year-old male presented with symptoms of appendicitis. Lab work revealed C. Minuta was found in his bloodstream. Upon removal of the appendix, his symptoms and blood levels of C. minuta disappeared. 
C Kropp, K Le Corf, K Relizani, K Tambosco, C Martinez, F Chain, G Rawadi, P Langella, S Claus, R Martin, P679 The keystone bacterium Christensenella minuta improves colitis in in vivo preclinical Inflammatory Bowel Disease models, Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Page S600, -jcc/jjab076.799
Christensenella is a Gram-negative, strictly anaerobic genus of bacteria first discovered in the human gut (3). Species within this genus are bacillar (rod-shaped), non-motile and non-spore forming (3, 4, 5). Christensenella minuta, Christensenella timonensis, and Christensenella massiliensis are currently the only known species of Christensenella, all of which were isolated from human stool samples (3, 4, 5). C. minuta was first recognized as a new taxon in 2012, after a Japanese study of the human microbiome isolated a previously uncharacterized bacterial strain from a sample of human stool (3).
The genomes of taxa within the Christensenella genus are approximately 2.56 to 3.03 million base pairs (Mbp) in length and contain between 2,500 and 2,900 genes encoding between 2,403 and 2,766 proteins (4, 5, 10). Approximately 79.7% of the genome of C. minuta is comprised of functional genes (10), encoding transcription factors as well as proteins for polysaccharide biosynthesis, translation and molecular transport (1, 2). Non-coding regions of the genome are associated with tRNA, rRNA and other RNA constructs as well as several pseudogenes. Genomic GC content within this genus ranges from 50.4 to 52.1% (4, 5, 10). 041b061a72